Advanced search
Publication Cover
Journal of Pain Research Volume 16, 2023 - Issue
Submit an article Journal homepage
184
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials

Kazumasa Saigoh1 Department of Neurology, Kindai University School of Medicine, Osaka, Japan
,
Takao Takeshima2 Headache Center, Department of Neurology, Tominaga Hospital, Osaka, Japan
,
Masami Nakai3 Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Osaka, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5159-0432
ORCID Icon,
Yoshiyuki Shibasaki4 Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
,
Miki Ishida5 Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan
,
Xiaoping Ning6 Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA
,
Steve Barash6 Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA
,
Yuki Isogai4 Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
&
Nobuyuki Koga7 Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokushima, JapanORCID Iconhttps://orcid.org/0000-0001-8034-7984
ORCID Icon show all
Pages 1311-1319 | Received 26 Oct 2022, Accepted 04 Apr 2023, Published online: 20 Apr 2023

References

  • Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808. doi:10.1177/0333102413485658
  • Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609. doi:10.1111/j.1468-2982.2009.01941.x
  • Pradeep R, Nemichandra SC, Harsha S, Radhika K. Migraine disability, quality of life, and its predictors. Ann Neurosci. 2020;27(1):18–23. doi:10.1177/0972753120929563
  • Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12(6):593–601. doi:10.1007/s10194-011-0388-3
  • Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13(5):361–378. doi:10.1007/s10194-012-0460-7
  • Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011;51(7):1058–1077. doi:10.1111/j.1526-4610.2011.01945.x
  • Ueda K, Ye W, Lombard L, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain. 2019;20(1):68. doi:10.1186/s10194-019-1012-1
  • Vikelis M, Spingos KC, Rapoport AM. A new era in headache treatment. Neurol Sci. 2018;39(Suppl 1):47–58. doi:10.1007/s10072-018-3337-y
  • Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350. doi:10.1038/s41582-018-0003-1
  • Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A. Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol. 2022;21(3):284–294. doi:10.1016/S1474-4422(21)00409-9
  • Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–2122. doi:10.1056/NEJMoa1709038
  • Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61(7):1092–1101. doi:10.1111/head.14169
  • Sakai F, Suzuki N, Ning X, et al. Long-term safety and tolerability of fremanezumab for migraine preventive treatment in Japanese outpatients: a multicenter, randomized, open-label study. Drug Saf. 2021;44(12):1355–1364. doi:10.1007/s40264-021-01119-2
  • Nagata R, Rafizadeh-Kabe JD. Japanese pharmaceutical and regulatory environment. Dialogues Clin Neurosci. 2002;4(4):470–474. doi:10.31887/DCNS.2002.4.4/rnagata
  • Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12(8):963–974. doi:10.1023/A:1026119331193
  • Takeshima T, Nakai M, Shibasaki Y, et al. Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients. J Headache Pain. 2022;23(1):24. doi:10.1186/s10194-022-01393-0
  • Bhugra D, Ventriglio A. Do cultures influence placebo response? Acta Psychiatr Scand. 2015;132(4):227–230. doi:10.1111/acps.12422
  • Winner PK, Spierings ELH, Yeung PP, et al. Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. Headache. 2019;59(10):1743–1752. doi:10.1111/head.13654
  • Bigal ME, Dodick DW, Krymchantowski AV, et al. TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology. 2016;87(1):41–48. doi:10.1212/WNL.0000000000002801

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.